Drug intelligence / Profile preview

CPI-182

Development stage: Preclinical
Lead developer: Corvus Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Not Specified (preclinical; Likely Intravenous Or Subcutaneous Based On Antibody Modality)

Overview

CPI-182 is a humanized monoclonal antibody targeting C-X-C motif chemokine receptor 2 (CXCR2), functioning as an antagonist. Developed by Corvus Pharmaceuticals (originator: Monash University), it is designed to inhibit neutrophil biology in chronic inflammatory diseases and potentially as an anti-cancer immunotherapy. By blocking CXCR2 (the interleukin 8B receptor), CPI-182 aims to reduce excessive recruitment and activation of neutrophils and, thus, pathological inflammation.

Other names: Anti-CXCR2 mAbAnti-CXCR-2 mAbAnti-CXCR 2 mAb

Targets

CXCR2 (C-X-C Motif Chemokine Receptor 2)

Beyond the preview

Go deeper on CPI-182.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPI-182.

Explore the full profile